SNY Sanofi ADR

$50.90

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending 2025-03-31
Expected on Apr 24, 2025
The Whisper Number
—
TWN v0.14

About Sanofi ADR

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Website: https://www.sanofi.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1121404
Address
54 RUE LA BOETIE, PARIS, FR
Valuation
Market Cap
$126.23B
P/E Ratio
20.52
PEG Ratio
0.87
Price to Book
1.42
Performance
EPS
$2.48
Dividend Yield
4.35%
Profit Margin
12.60%
ROE
7.30%
Technicals
50D MA
$54.87
200D MA
$52.90
52W High
$60.12
52W Low
$44.24
Fundamentals
Shares Outstanding
2B
Target Price
$63.97
Beta
0.48

SNY EPS Estimates vs Actual

● Estimated
● Actual

SNY News & Sentiment

Apr 18, 2025 • GlobeNewswire NEUTRAL
Regeneron Provides Update on EYLEA HD® ( aflibercept ) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration ( FDA ) has issued a complete response letter ( CRL ) regarding the supplemental Biologics License Application ( sBLA ) for the ...
Apr 18, 2025 • Benzinga NEUTRAL
Dupixent® ( dupilumab ) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria ( CSU ) - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y. and PARIS, April 18, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.
Apr 18, 2025 • Benzinga NEUTRAL
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo
Apr 18, 2025 • GlobeNewswire NEUTRAL
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria ...
Apr 18, 2025 • GlobeNewswire NEUTRAL
Dupixent® ( dupilumab ) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria ( CSU )
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo ...
Apr 18, 2025 • Motley Fool SOMEWHAT-BULLISH
This Beaten-Down Artificial Intelligence ( AI ) Stock Just Got Some Great News: Time to Buy?
Artificial intelligence ( AI ) is taking over the world. Individuals and corporations are implementing the technology in their day-to-day lives and operations. governmental institutions are doing the same. The U.S. Food and Drug Administration ( FDA ) recently announced it would phase out animal ...
Sentiment Snapshot

Average Sentiment Score:

0.103
50 articles with scored sentiment

Overall Sentiment:

Neutral

SNY Reported Earnings

Financials